A retrospective Study of Comorbidity-Associated Anaemia in Hemodialysis Patients at Tarhuna Teaching Hospital
Keywords:
chronic kidney disease, anemia, hemodialysis, erythropoietin, tardyferon tabletAbstract
Chronic kidney disease is a condition that affects the body's ability to maintain metabolic, fluid electrolytes, balance and erythropoietin secretion. Hemodialysis is the most common treatment for advanced and permanent kidney failure, but anemia is one of the most common complications.
Materials and Methods: This study was conducted from August 20 to December 20, 2022. It was collected from statistics that were issued by the archive of the (hemodialysis unit, Teaching Hospital of Tarhona), and it aimed to estimate the prevalence of anemia in hemodialysis patients and evaluate its occurrence in both male and female individuals, and data were analyzed by (Microsoft excel version 2010) and SPSS programmer (SPSS version 22). The study involved 117 reported cases that were investigated; males were 73 and females were 44.
It was found that the prevalence of anemia in patients with dialysis is very high by 93.2% (109/117), and their ages range between 13 to 82 years, where the highest percentage of patients with kidney failure is more than 60 years of age (37 cases) out of a total of 117 cases (31.6%). The number of men in this study was 73 by 62.4% and the number of women was 44 by 37.6%. While the percentage of patients taking "Erythropoietin type alpha in addition to Tardyferon tablet is (52.1%), while (47.9%) of them take" Erythropoietin type alpha "only. Patients suffer from 31.6% of diabetes, 62.4% of High blood pressure, 11.1 from cardiovascular disease.
This study concluded that most of the patients suffer from anemia. Oral iron supplementation did not improve patients' hemoglobin levels.
Recommendations: According to the high incidence of anemia among chronic kidney disease, it is highly recommended that routine hemoglobin checks be followed, and it is highly recommended to take iron intravenously instead of orally. It is highly recommended to take vitamin B12 and folic acid.
References
Almansour, N. A., Syed, H. F., Khayat, N. R., Altheeb, R. K., Juri, R. E., Alhiyafi, J., Alrashed, S., & Olatunji, S. O. (2019). Neural network and support vector machine for the prediction of chronic kidney disease: A comparative study. Computers in biology and medicine, 109, 101–111.
Amoako, Y. A., Laryea, D. O., Bedu-Addo, G., Andoh, H., & Awuku, Y. A. (2014). Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. The Pan African Medical Journal, 18.
Anemia. Hematology/oncology clinics of North America, 30(2), 247–308.
Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology : JASN, 23(10), 1631–1634.
Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020). Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. Journal of the American Society of Nephrology : JASN, 31(3), 456–468.
Besarab, A., & Coyne, D. W. (2010). Iron supplementation to treat anemia in patients with chronic kidney disease. Nature Reviews Nephrology, 6(12), 699-710.
Beto, J., Bhatt, N., Gerbeling, T., Patel, C., & Drayer, D. (2019). Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 29(1), 2–15.
Chatzimanouil, M. K. T., Wilkens, L., & Anders, H. J. (2019). Quantity and Reporting Quality of Kidney Research. Journal of the American Society of Nephrology : JASN, 30(1), 13–22.
Elamouri, J. (2021). Family history in patients with end-stage renal disease on hemodialysis in Tripoli, Libya. Ibnosina Journal of Medicine and Biomedical Sciences, 13(01), 14-19.
Freedman, B. I., Volkova, N. V., Satko, S. G., Krisher, J., Jurkovitz, C., Soucie, J. M., & McClellan, W. M. (2005). Population-based screening for family history of end-stage renal disease among incident dialysis patients. American journal of nephrology, 25(6), 529-535.
Habas, E., Rayani, A., Habas, A. M., Akbar, R. A., Khan, F. Y., & Elzouki, A. N. (2022). Anemia in Chronic Kidney Disease Patients: An Update. Ibnosina Journal of Medicine and Biomedical Sciences.
Isakova, T., Nickolas, T. L., Denburg, M., Yarlagadda, S., Weiner, D. E., Gutiérrez, O. M., Bansal, V., Rosas, S. E., Nigwekar, S., Yee, J., & Kramer, H. (2017). KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). American journal of kidney diseases : the official journal of the National Kidney Foundation, 70(6), 737–751.
Jager, K. J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V., & Zoccali, C. (2019). A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney international, 96(5), 1048–1050.
Juma, A. (2012). Prevalence of Anemia and its associated factors in patients with Chronic Kidney Disease at Muhimbili National Hospital Dar es Salaam (Doctoral dissertation, Muhimbili University of health and Allied Sciences).
Kassebaum, N. J., & GBD 2013 Anemia Collaborators (2016). The Global Burden of
Kilonzo, K. G. (2010). CHRONIC RENAL FAILURE AND ASSOCIATED RISK FACTORS AMONG MEDICAL ADMISSIONS AT KCMC, MOSHI (Doctoral dissertation)
Lee, K. H., Ho, Y., & Tarng, D. C. (2021). Iron Therapy in Chronic Kidney Disease: Days of Future Past. International journal of molecular sciences, 22(3), 1008.
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M. H., Lv, J., Garg, A. X., Knight, J., Rodgers, A., Gallagher, M., Kotwal, S., Cass, A., & Perkovic, V. (2015). Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet (London, England), 385(9981), 1975–1982.
Lukito, W., & Wahlqvist, M. L. (2020). Intersectoral and eco-nutritional approaches to resolve persistent anemia in Indonesia. Asia Pacific journal of clinical nutrition, 29(Suppl 1), S1–S8.
Ngai, M., Lin, V., Wong, H. C., Vathsala, A., & How, P. (2014). Vitamin D status and its association with mineral and bone disorder in a multi-ethnic chronic kidney disease population. Clinical nephrology, 82(4), 231–239.
Shettigar, R., Samaranayaka, A., Schollum, J. B. W., Wyeth, E. H., Derrett, S., & Walker, R. J. (2021). Predictors of Health Deterioration Among Older New Zealanders Undergoing Dialysis: A Three-Year Accelerated Longitudinal Cohort Study. Canadian journal of kidney health and disease, 8, 20543581211022207.
Toft, G., Heide-Jørgensen, U., van Haalen, H., James, G., Hedman, K., Birn, H., Christiansen, C. F., & Thomsen, R. W. (2020). Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. Journal of nephrology, 33(1), 147–156.
Vaziri, N. D., Kalantar-Zadeh, K., & Wish, J. B. (2016). New Options for Iron Supplementation in Maintenance Hemodialysis Patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 67(3), 367–375).
Wilhelm-Leen, E. R., & Winkelmayer, W. C. (2015). Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 66(1), 69–74.
World, Health, Organization (2015). The global prevalence of anaemia in 2011.
Mustafa khalifa Ali. (2025). Prevalence of ABO blood grouping among chronic kidney disease patients on hemodialysis in Tripoli. Libya. Journal of Libyan Academy Bani Walid, 1(4), 72–78. https://doi.org/10.61952/jlabw.v1i4.270
Nagah Bobtina, Intesar Elmasli, Ali Bubteina, & Maryam Akhwater. (2025). The effect of risk factors, heredity and chronic diseases on property incidence of kidney disease. Journal of Libyan Academy Bani Walid, 1(2), 39–50. https://doi.org/10.61952/jlabw.v1i2.20
